Ambrx granted Zhejiang rights to develop and commercialize Ambrx's ARX788 to treat breast cancer in China

Ambrx Inc.

U.S. / Private Biopharma

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Zhejiang Medicine Co. Ltd.

China / Small-Cap Biopharma (<$1 billion)

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced